Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

JOHNS HOPKINS UNIVERSITY

🇳🇦Namibia

Country: 🇳🇦Namibia

Ownership: -

Established: 1876-01-01

Employees: 19.4K

Market Cap: -

Website: https://www.jhu.edu/

Clinical Trials

The Effect of Weight Loss and Exercise on Knee Osteoarthritis

Not Applicable

Completed

Conditions: Osteoarthritis, Knee

First Posted Date: 2003-05-29

Last Posted Date: 2017-09-26

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 160

Registration Number: NCT00061490

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Child and Adolescent Anxiety Disorders (CAMS)

Phase 3

Completed

Conditions: Social Phobia
Generalized Anxiety Disorder
Anxiety Disorders

Interventions: Drug: Sertraline (SRT)
Drug: Placebo
Behavioral: Cognitive Behavioral Therapy (CBT)

First Posted Date: 2003-01-23

Last Posted Date: 2017-09-19

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 488

Registration Number: NCT00052078

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
NYSPI/Columbia University, New York, New York, United States

and more 3 locations

OmniHeart Trial: Macronutrients and Cardiovascular Risk

Not Applicable

Completed

Conditions: Cardiovascular Diseases
Atherosclerosis
Hypertension
Heart Diseases

First Posted Date: 2003-01-13

Last Posted Date: 2018-10-04

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 164

Registration Number: NCT00051350

Genetic Modifiers of Cystic Fibrosis: Sibling Study

Completed

Conditions: Cystic Fibrosis
Lung Diseases

First Posted Date: 2002-05-21

Last Posted Date: 2016-08-31

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 3459

Registration Number: NCT00037778

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics - 1

Phase 3

Completed

Conditions: Substance-Related Disorders

First Posted Date: 2002-04-08

Last Posted Date: 2017-01-12

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 440

Registration Number: NCT00033007

Locations: 🇺🇸
MATRIX/LA Addictions Research, Los Angeles, California, United States
🇺🇸
Crossroads Managed Care Systems - Alamosa, Alamosa, Colorado, United States
🇺🇸
Arapahoe/Douglas Mental Health Network, Littleton, Colorado, United States

and more 8 locations

Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1

Phase 3

Completed

Conditions: Substance-Related Disorders

First Posted Date: 2002-04-08

Last Posted Date: 2017-01-12

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 390

Registration Number: NCT00033020

Locations: 🇺🇸
Aegis Medical Systems, Inc., Bakersfield, California, United States
🇺🇸
Oasis Clinic, Washington, District of Columbia, United States
🇺🇸
Glenwood Life Counseling Center, Baltimore, Maryland, United States

and more 4 locations

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

Phase 2

Completed

Conditions: Cerebral Hemorrhage

First Posted Date: 2002-01-11

Last Posted Date: 2015-03-25

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 30

Registration Number: NCT00029315

Locations: 🇺🇸
The Johns Hopkins University, Baltimore, Maryland, United States

Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus

Phase 2

Completed

Conditions: Pemphigus

First Posted Date: 2001-02-02

Last Posted Date: 2008-10-02

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 35

Registration Number: NCT00010413

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

Phase 2

Completed

Conditions: Anemia, Hemolytic, Autoimmune
Felty Syndrome
Purpura, Thrombocytopenic
Autoimmune Diseases

First Posted Date: 2001-02-02

Last Posted Date: 2008-09-10

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 32

Registration Number: NCT00010387

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

Not Applicable

Completed

Conditions: Systemic Lupus Erythematosus
Antiphospholipid Antibody Syndrome

First Posted Date: 2001-02-02

Last Posted Date: 2005-06-24

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 35

Registration Number: NCT00010400

Locations: 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy